Physician profile
Janis E Collins
NPI 1427009778
$3,019.99
in general payments reported to CMS, 2019-2025
29 companies · $631 in 2025
The $631 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $463 · 2023: $1,055 · 2024: $734 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $505.89 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $421.94 | 2022-2025 | |
| Pfizer INC. | $287.02 | 2022-2025 | |
| Abbott Laboratories | $212.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $174.10 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $143.14 | 2022-2024 | Otezla, Repatha, Evenity |
| Corcept Therapeutics | $135.36 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.18 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $103.98 | 2022-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $101.93 | 2021-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $98.37 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.18 | 2021-2024 | Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $79.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $72.76 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.61 | 2021-2024 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.36 | 2023 | Shingrix, Arexvy |
| Boston Scientific Corporation | $45.37 | 2024 | Watchman Access System |
| Mylan Specialty L.P. | $39.71 | 2023-2024 | Yupelri |
| Medtronic, INC. | $35.22 | 2021-2024 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $34.41 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $34.19 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $30.46 | 2024 | Uzedy, Austedo Xr |
| Corium, LLC | $28.83 | 2023 | Adlarity |
| Optinose US, INC. | $23.66 | 2024 | |
| Ge Healthcare | $23.50 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.09 | 2023 | Keveyis |
| Seqirus USA INC | $18.81 | 2025 | Fluad, Flucelvax |
| Astellas Pharma US INC | $14.48 | 2024 | Veozah |
| Gilead Sciences, INC. | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janis Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.